Heparin prevents blood clots by supercharging one of your body’s own natural anticoagulant proteins. Specifically, it binds to a protein called antithrombin and makes it up to 1,000 times faster at shutting down the chain reaction that forms clots. This makes heparin one of the most widely used blood thinners in hospitals, where its rapid onset and ability to be quickly reversed give it a role in everything from surgery to emergency treatment of blood clots.
The Clotting Cascade and Antithrombin
To understand heparin, it helps to know a little about how clots form. Your blood contains a series of proteins called clotting factors that activate each other in sequence, like dominoes falling. The end result is a mesh of fibrin that traps blood cells and seals a wound. This chain reaction is called the coagulation cascade.
Your body keeps this system in check with antithrombin, a protein that circulates in your blood and acts as a natural brake. Antithrombin is responsible for up to 80% of the body’s ability to inhibit thrombin, the key enzyme that converts fibrinogen into the fibrin strands that hold a clot together. Antithrombin also blocks two other important clotting factors (called factor IXa and factor Xa) that sit upstream in the cascade. On its own, though, antithrombin works slowly. That’s where heparin comes in.
How Heparin Speeds Up the Process
Heparin is a long chain of sugar molecules studded with negatively charged sulfate groups. A specific five-sugar sequence within that chain locks onto a positively charged binding site on antithrombin’s surface. When this connection is made, antithrombin changes shape in a way that dramatically increases its ability to grab and neutralize clotting factors. The result is a 1,000-fold acceleration of an anticoagulant process that was already happening, just far too slowly to prevent a dangerous clot.
Once antithrombin latches onto a clotting factor, the two form a stable complex that permanently removes that clotting factor from circulation. Heparin then detaches and moves on to activate another antithrombin molecule, repeating the cycle.
Unfractionated vs. Low Molecular Weight Heparin
There are two main forms of heparin used in medicine, and their differences come down to chain length. Unfractionated heparin (UFH) is a mix of long sugar chains of varying sizes. It blocks both thrombin and factor Xa roughly equally. Low molecular weight heparin (LMWH) is made by breaking those chains into shorter fragments, which shifts the balance: LMWH has a much higher ratio of anti-factor Xa activity compared to its effect on thrombin.
This structural difference has practical consequences. LMWH has greater bioavailability, meaning more of the injected dose actually reaches your bloodstream. It also has a longer half-life (roughly two to four times that of UFH) and produces a more predictable anticoagulant effect. That predictability means LMWH can often be given as a fixed, weight-based dose injected under the skin without the need for frequent blood tests. UFH, by contrast, is typically given through an IV drip in the hospital and requires regular monitoring.
How Quickly It Works and Wears Off
When given intravenously, unfractionated heparin begins working almost immediately. Its half-life, the time for half the drug’s effect to disappear, is roughly 60 to 90 minutes for a typical dose. Larger doses take longer to clear: a very high dose in a 70-kilogram adult can have a half-life closer to two and a half hours, while a small dose may clear in as little as 30 minutes. This short, dose-dependent duration is one of heparin’s advantages in hospital settings, because if bleeding occurs, the effect fades quickly.
When injected under the skin rather than into a vein, heparin absorbs more slowly and its effects are more gradual. LMWH, designed for subcutaneous injection, maintains therapeutic levels for much longer, often allowing once- or twice-daily dosing.
What Heparin Is Used For
Heparin is a workhorse in hospitals. Its most common uses include:
- Treating blood clots: deep vein thrombosis (clots in the legs) and pulmonary embolism (clots in the lungs)
- Preventing clots during surgery: especially heart surgery and procedures involving cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO)
- Bridging therapy: providing immediate anticoagulation while a slower-acting oral blood thinner takes effect
- Dialysis and blood transfusions: keeping blood from clotting inside tubing and machines
- Atrial fibrillation: preventing stroke-causing clots during cardioversion or while transitioning to oral medications
- Acute limb ischemia: restoring blood flow when an artery in the arm or leg is suddenly blocked
Monitoring During Treatment
Because unfractionated heparin’s effect varies from person to person, doctors use a blood test called the activated partial thromboplastin time (aPTT) to check whether the dose is in the right range. The standard target is an aPTT 1.5 to 2.5 times the upper limit of the lab’s normal reference range. In practice, that often translates to somewhere around 65 to 130 seconds, though each hospital’s numbers differ slightly based on their reagents and equipment.
LMWH doesn’t reliably affect the aPTT, so when monitoring is needed, a different test measuring anti-factor Xa activity is used instead. Most patients on LMWH don’t need routine monitoring at all. The exceptions are people with significantly impaired kidney function (since LMWH is cleared by the kidneys), those who are pregnant, and those with very high body weight, where the standard dose may not produce the expected blood levels.
Reversing Heparin in an Emergency
One of heparin’s practical advantages is that it can be reversed quickly. A protein called protamine binds directly to heparin and neutralizes it. The standard ratio is 1 milligram of protamine for every 100 units of circulating heparin, though recent research in cardiac surgery suggests the dose can often be reduced to 0.8 or even 0.75 milligrams per 100 units without increasing bleeding risk. Protamine is less effective at reversing LMWH, neutralizing the anti-thrombin component but only partially blocking its anti-factor Xa activity.
Heparin-Induced Thrombocytopenia
The most serious side effect unique to heparin is an immune reaction called heparin-induced thrombocytopenia, or HIT. In this condition, the immune system produces antibodies that target a complex formed between heparin and a protein released from platelets. These antibodies then bind to and activate platelets, triggering a paradoxical state: platelet counts drop (because they’re being consumed) while the risk of dangerous new clots actually increases.
The immune reaction itself is fairly common, with 8% to 50% of heparin-exposed patients developing the antibodies. But clinically significant HIT, with low platelet counts and clotting complications, is much rarer, affecting roughly 0.2% to 3% of patients depending on the clinical setting. HIT typically develops 5 to 10 days after starting heparin. If it occurs, all heparin products must be stopped immediately and an alternative anticoagulant started. A prior history of HIT within the last 100 days, or detectable circulating HIT antibodies, is an absolute contraindication to using heparin again.
Who Should Not Receive Heparin
Beyond HIT, heparin is contraindicated in people with active major bleeding, recent bleeding in the brain, severe uncontrolled high blood pressure, bleeding disorders, active peptic ulcer disease, and recent surgery on the eyes or nervous system. It’s also avoided after traumatic injuries where internal bleeding is a concern. These restrictions apply to both unfractionated heparin and LMWH.